Today: 3 March 2026
Subscribe
Browse Category

Stock Market 9 October 2025

Shocking IRS Update: New 2026 Tax Brackets Slashed for Millions – Here’s How Much You’ll Save

Shocking IRS Update: New 2026 Tax Brackets Slashed for Millions – Here’s How Much You’ll Save

The IRS released 2026 tax brackets and deductions, raising the standard deduction to $32,200 for joint filers and $16,100 for singles. All income thresholds shift higher, with a single earner making $50,000 now taxed at 12% instead of 22%. Marginal rates remain at 10%–37%. The changes follow the “One Big Beautiful Bill” signed in July 2025, which made most 2017 tax cuts permanent.
9 October 2025
··
CIFR Stock Skyrockets 320% After Google-Backed AI Mining Deal – Bubble or Boom?

CIFR Stock Skyrockets 320% After Google-Backed AI Mining Deal – Bubble or Boom?

Cipher Mining shares closed at $17.60 on Oct. 8, up nearly 12% after announcing a $3 billion, Google-backed AI hosting deal at its new Barber Lake site. The company’s market cap stands near $6 billion, with the stock up over 320% year-to-date. Cipher remains unprofitable, reporting a Q2 net loss of $46 million on $44 million revenue. Former CFO Ed Farrell retired Oct. 14, replaced by Greg Mumford.
9 October 2025
··
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero shares jumped nearly 19% to $55 on October 9, 2025 after Novo Nordisk announced a $5.2 billion buyout at $54 per share plus a $6 contingent payment. Novo will pay $4.7 billion upfront and another $500 million if Akero’s lead drug, efruxifermin, wins FDA approval by 2031. The deal has board approval and is expected to close by late 2025, pending regulatory and shareholder clearance.
9 October 2025
···
Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype?

Turn Therapeutics shares surged to around $23 midday Oct. 9 after opening at $24.50, following a prior close of $7. Market cap jumped to over $500 million from under $100 million. The stock debuted on Nasdaq Oct. 8 via direct listing and has traded with extreme volatility, more than tripling in value amid speculative interest. No new FDA approvals were announced this week.
9 October 2025
··
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

NTLA surged past $26 on Oct. 8, 2025, after positive Phase 1 data for its ATTR program showed sustained TTR protein knockdown and no new safety issues. Trading volume spiked to 17 million shares. Wall Street remains bullish, with most analysts rating NTLA a Buy and targets averaging $31.7. Intellia holds $630–707 million in cash and expects funding to last into 2027.
9 October 2025
··
Uzbekistan’s Big Bet: Import Fair 2025 Sparks a ‘Made in Uzbekistan’ Boom

Uzbekistan’s Big Bet: Import Fair 2025 Sparks a ‘Made in Uzbekistan’ Boom

Uzbekistan launched its first international Import Fair in Tashkent, unveiling $8.5 billion in new investment projects to boost local manufacturing and reduce imports. At the same time, 66 Uzbek firms promoted exports at MSV-2025 in Brno. GDP rose 7.2% year-on-year in early 2025, with FDI reaching $11.9 billion in 2024. Major foreign companies, including Inditex, praised recent trade reforms.
9 October 2025
·
United Airlines Stock Skyrockets on Travel Boom: Is $130 Next for UAL?

United Airlines Stock Skyrockets on Travel Boom: Is $130 Next for UAL?

United Airlines shares closed at $98.09 on Oct 8, 2025, up 1.5%, and surged to $104 in early trading Oct 9. The stock rebounded from $94 lows last week, tracking sector gains after Delta’s strong Q3 results. United announced new European and Middle Eastern routes for summer 2026. The ongoing U.S. government shutdown has caused flight delays but has not yet disrupted airline operations.
9 October 2025
··
Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Bluejay Diagnostics (BJDX) Stock Skyrockets on Sepsis Test Hopes – What Investors Need to Know

Bluejay Diagnostics shares soared over 142% to $4.53 on Oct. 9 after announcing an expanded manufacturing partnership with SanyoSeiko. Trading volume hit 40 million shares, far above the 154,000 average. The company, which has no product revenue and only $5.7 million in cash, recently cut its workforce by 90%. Symphony, its lead diagnostic product, is not yet FDA-cleared.
9 October 2025
··
American Airlines (AAL) Stock Takes Off on Travel Demand – Will It Keep Climbing or Hit Turbulence?

American Airlines (AAL) Stock Takes Off on Travel Demand – Will It Keep Climbing or Hit Turbulence?

American Airlines shares traded near $12 on Oct. 9, 2025, down 34% year-to-date and 15% in the past month. The stock rose 3–4% after Delta’s strong Q3 results, but American still faces weak domestic demand, high debt, and rising labor costs. Analysts remain split, with price targets ranging from $8 to $17. The company will report Q3 earnings later this month.
9 October 2025
··
Serve Robotics (SERV) Stock Soars on DoorDash Deal – The Next Big Bet in AI Delivery?

Serve Robotics (SERV) Stock Soars on DoorDash Deal – The Next Big Bet in AI Delivery?

Serve Robotics announced a partnership with DoorDash on October 9, 2025, to deploy its autonomous delivery robots in Los Angeles. The news sent SERV shares up 15% in one day. The company, which went public in April 2024, operates about 400 robots and plans to expand to 2,000 by year-end. Serve’s market cap stands near $800 million, though annual revenue remains under $2 million.
9 October 2025
··
Powell’s Next Move Could Make or Break 2025’s Record Stock Rally

Powell’s Next Move Could Make or Break 2025’s Record Stock Rally

The S&P 500 and Nasdaq closed at record highs on Oct. 8, with the S&P up 0.6% to 6,753.72 and the Nasdaq rising 1.1% to 23,043.38. Gold surged past $4,000/oz for the first time, peaking at $4,078 before retreating slightly. Tech stocks soared, led by AMD’s 24% jump after an OpenAI deal. The Fed signaled more rate cuts after its first 2025 reduction, though inflation concerns remain.
9 October 2025
·····
Wolfspeed WOLF Stock’s Wild Comeback: From Bankruptcy to Boom – Price, News & Expert Forecasts

Wolfspeed WOLF Stock’s Wild Comeback: From Bankruptcy to Boom – Price, News & Expert Forecasts

Wolfspeed stock surged over 1,000% intraday on September 29, 2025, after emerging from Chapter 11 bankruptcy and slashing debt by about 70%. Shares traded near $30.36 on October 9, giving a market cap of $0.7–0.8 billion. Most old equity was wiped out, with existing shareholders retaining only 3–5% of the company. Analysts rate the stock a Hold, with average 12-month price targets of $8–10.
9 October 2025
·
Ferrari Stock Skids as EV Ambitions Shift: Inside RACE’s High-Octane Gamble

Ferrari Stock Skids as EV Ambitions Shift: Inside RACE’s High-Octane Gamble

Ferrari shares plunged nearly 12% to about $430 after its Capital Markets Day, erasing year-to-date gains and leaving the stock flat versus a year ago. Market cap now stands near $75 billion, more than double Porsche’s. The company announced €3.5 billion in dividends and a €3.5 billion buyback through 2030. Insiders, led by Exor, control about 48% of voting power.
9 October 2025
··
PepsiCo (PEP) Stock: Q3 Earnings Surprise, “Ozempic Effect” Fears & Activist Investor Shake-Up – What’s Next?

PepsiCo (PEP) Stock: Q3 Earnings Surprise, “Ozempic Effect” Fears & Activist Investor Shake-Up – What’s Next?

PepsiCo shares trade near $139, down 6% in a month and 22% below last year’s high. Q3 revenue rose 2.6% to $23.94 billion, topping estimates, but North American snack and beverage volumes fell. Elliott Management disclosed a $4 billion stake, urging changes. Steve Schmitt was named CFO on Oct. 9, replacing retiring Hugh Johnston.
9 October 2025
··
Tilray’s 300% Rally and Surprise Profit: Is the Cannabis Comeback Real?

Tilray’s 300% Rally and Surprise Profit: Is the Cannabis Comeback Real?

Tilray Brands posted record Q1 2026 revenue of $209.5 million and a surprise net profit of $1.5 million, sending shares up over 10% pre-market. The stock has quadrupled since July 2025, lifted by optimism over potential U.S. cannabis reform and recent political endorsements. Wall Street remains cautious, with a consensus “Hold” rating and a $1.90 price target. Volatility remains high as investors watch for policy changes and earnings updates.
9 October 2025
··
Jamie Dimon’s Dire Warning: “Serious” Stock Market Correction Could Hit Soon

Jamie Dimon’s Dire Warning: “Serious” Stock Market Correction Could Hit Soon

JPMorgan CEO Jamie Dimon warned U.S. stocks could face a “significant correction” within 6 to 24 months, citing geopolitical tensions, heavy fiscal spending, and global military buildups. He said markets are showing “unrestrained optimism” and compared current AI-driven rallies to past bubbles. Dimon remains only “mildly” concerned about inflation but said a recession is still possible by 2026.
9 October 2025
·
UiPath Stock Skyrockets on ‘Agentic AI’ Boom – AI Deals & Earnings Fuel Rally

UiPath Stock Skyrockets on ‘Agentic AI’ Boom – AI Deals & Earnings Fuel Rally

UiPath shares jumped nearly 20% in early October 2025, hitting $15.58 after new AI partnerships with OpenAI, Google, NVIDIA, and Snowflake. Quarterly revenue rose 14.6% to $362 million, with a swing to a GAAP profit. Management raised full-year guidance, but analysts remain cautious, with most ratings at Hold and a price target near $13–14. Trading volumes doubled as investors reacted to the AI announcements.
9 October 2025
··
Mystery $75 M Bet Propels Tiny POET Technologies to New Highs Amid AI Frenzy

Mystery $75 M Bet Propels Tiny POET Technologies to New Highs Amid AI Frenzy

POET Technologies announced a $75 million private placement from a single institutional investor on Oct. 7, raising its cash reserves above $150 million with no debt. Shares surged 23.5% to $7.88, trading volume hit 41 million, and call option activity spiked as retail traders piled in. The company remains pre-revenue and unprofitable, with its valuation far ahead of fundamentals.
9 October 2025
···
1 … 1,279 1,280 1,281 1,282 1,283 … 1,323
Go toTop